Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$90MCash on Hand
16.9mo Cash Runway
Follow RZLT by emailGet an email when RZLT reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about RZLT, unsubscribe in one click. Privacy
📣 What RZLT Says Is Next
in 2027 · Ersodetug: “Key highlights include: · Potential $5 billion combined market opportunity. · Plan to submit a BLA for ersodetug for one or potentially both indications in 2027.”
Company press release, Nov 5, 2026 · SEC filing
this quarter · Ersodetug: “In light of expected topline results this quarter from the Company’s upLIFT study in tumor HI and the potential for an additional pre-BLA meeting for that indication should the study results support a submission, the Company will evaluate its overall BLA submission strategy for potentially both programs following the announcement of upLIFT study results.”
Company press release, Oct 5, 2026 · SEC filing
second half of 2026 · “Enrollment is in progress and topline results are expected in the second half of 2026.”
Company press release, May 12, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 16, 2026 ·
Financing Rezolute priced an underwritten offering of 22,040,976 common shares at $3.87 per share, plus pre-funded warrants for up to 3,800,000 shares at $3.869 each, with expected gross proceeds of about $100 million. Form 8-K · SEC filing · Press release
Nov 13, 2026 ·
Clinical trial Rezolute reported that the primary endpoint of its Phase 3 upLIFT study of ersodetug in tumor hyperinsulinism was achieved, with 13 of 16 enrolled participants meeting the responder criterion, 12 of whom also fully discontinued IV glucose. Full topline results are expected by mid-December 2026. Form 8-K · SEC filing · Press release
Nov 13, 2026 ·
Financing Rezolute proposes a registered public offering of common stock and pre-funded warrants, with Morgan Stanley as lead book-running manager. Amounts and pricing are blank in this preliminary prospectus. The last reported Nasdaq sale price was $4.07 per share on November 11, 2026. Form 424B5 · SEC filing
Nov 5, 2026 ·
Earnings Reported Q1 fiscal 2027 net loss of $18.5 million versus $18.2 million a year ago, with R&D of $12.8 million and G&A of $6.6 million. Cash and investments were $90.0 million. Topline results from the upLIFT tumor HI study are expected by mid-December 2026, and a BLA for one or both indications is planned for 2027. Form 8-K · SEC filing · Press release
Nov 5, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 5, 2026 ·
Financing Rezolute filed a shelf registration statement on Form S-3 for up to $400,000,000 in securities, including debt, common stock, preferred stock, warrants, subscription rights, purchase contracts, depositary shares and units. Amounts and prices for any specific offering will be set in later prospectus supplements. Form S-3 · SEC filing
Oct 29, 2026 ·
Clinical trial Rezolute furnished an investor presentation on its website as Exhibit 99.1. It reports $108 million in cash with runway through Q1 2028, and topline data for congenital hyperinsulinism is expected December 2026. The sunRIZE primary endpoint was not met due to confounding placebo effects. Form 8-K · SEC filing · Press release
Oct 21, 2026 ·
Shareholder vote Rezolute will hold its 2027 annual meeting virtually on December 2, 2026. Stockholders will vote on seven board nominees, ratifying Grant Thornton LLP as auditor for fiscal 2027, a non-binding say-on-pay vote, and a proposal to raise authorized common stock from 165,000,000 to 225,000,000 shares. Form DEF 14A · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Sep 2027 · Phase 3 · Recruiting · A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism Registry primary completion date, not a results date
Nov 2025 · Phase 3 · Active Trial · RZ358 Treatment for Congenital Hyperinsulinism Registry date passed, readout not confirmed
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
RZLT holds $90M in cash and short-term investments (as of Sep 30, 2026) and burns about $15.9M/quarter from operations,
an estimated runway of 16.9 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:18 · Low
Cash runway 17 months +18
Shelf registration (S-3, Nov 2026) +10
Raised after last reported balance sheet (Nov 2026) -10
Share count 96,728,913 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full RZLT picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for RZLT and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.